Clinical trial Recruiting at 1 site Interventional Ages 45 and up

Monitoring patients with precursors to gastric cancer

Official title: SUrveillance of PREMalignant Stomach - Individualized Endoscopic Follow-up

Run by Instituto Portugues de Oncologia, Francisco Gentil, Porto · NCT04613570 · Data updated 2026-11-12

This study is testing the best ways to monitor people over 45 with early signs of stomach cancer to help keep them safe and healthy.

More Gastric Cancer trials

Quick facts

Study typeInterventional
Ages45 Years and up
SexAll
Enrollment912 (estimated)
SponsorInstituto Portugues de Oncologia, Francisco Gentil, Porto
Academic / other
Locations1 site (Porto)
StatusRecruiting
StartedJanuary 2, 2021
Main results expectedDecember 31, 2026
Study endsDecember 31, 2026
Registry record updatedMarch 31, 2022
Trial IDNCT04613570 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are individuals over 45 years old with known gastric premalignant conditions scheduled for upper GI endoscopy.

Probably not a fit

Patients with a history of previous gastrectomy, endoscopic resection of neoplastic lesions, or hereditary syndromes increasing gastric cancer risk may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate patients with premalignant gastric conditions, such as atrophic gastritis and intestinal metaplasia, to determine the best methods for their identification and follow-up. It will utilize high-resolution endoscopy and validated histological scales to assess the risk of gastric cancer over time. The study will involve multiple gastroenterology departments across various countries and will focus on patients over 45 years old who are scheduled for upper gastrointestinal endoscopy. By analyzing clinical, histological, and endoscopic factors, the study seeks to establish optimal surveillance protocols for these patients.

Why it matters

Potential benefit: If successful, this study could lead to improved surveillance strategies that reduce the risk of gastric cancer in at-risk patients.

How similar studies have gone: Other studies have shown success in using endoscopic surveillance for gastric cancer precursors, but this approach is novel in its comprehensive evaluation of multiple factors.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients scheduled for upper GI endoscopy with indication for gastric biopsies, including those with known gastric pathology (e.g. auto-immune gastritis) or premalignant conditions (e.g patients under surveillance because of atrophic gastritis);
* Age above 45 years old

Exclusion Criteria:

* History of previous gastrectomy;
* History of endoscopic resection of neoplastic lesion
* History of previous gastric dysplasia (even with no detectable lesion)
* Hereditary syndromes that increase gastric cancer risk (familial adenomatous polyposis; Lynch syndrome)
* Serious comorbidities (ASA 3 or more)
* Medication with anticoagulants

Where it's running

  • IPO-Porto
    Porto, Portugal
    Recruiting

Study contacts

  • Principal investigator: Pedro Pimentel-Nunes, MD PhD — Instituto Português de Oncologia do Porto, Francisco Gentil
  • Study coordinator: Pedro Pimentel-Nunes, MD PhD
  • Email: pedro.nunes@ipoporto.min-saude.pt
  • Phone: +35122508400

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.